Scius Communications
  • Home
  • About Us
    • Katja Stout
    • Daniel Gooch
    • Sue Charles
    • Kari Bennett
    • Caroline Cross
    • Leyla Karabekmez
  • Experience
    • Corporate Communications
    • Financial Communications
    • Media Relations
    • Partnering Communications
    • Marketing Communications
    • Digital Communications
    • Internal Communications
    • Case Studies
  • News & Events
  • Careers
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Blog - Latest News

LEX Diagnostics Appoints Ed Farrell as Chief Executive Officer

11 January 2023

CAMBRIDGESHIRE, United Kingdom, Feb. 21, 2023  – LEX Diagnostics announces the appointment of Ed Farrell as its new Chief Executive Officer.

Read full release.

https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png 0 0 Katja Stout https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png Katja Stout2023-01-11 10:32:332023-02-22 10:33:43LEX Diagnostics Appoints Ed Farrell as Chief Executive Officer
You might also like
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
ExeVir Bio secures EUR 25 million venture debt financing from European Investment Bank
Tay Therapeutics Announces Licensing to VYNE Therapeutics of Oral BET Inhibitor for immuno-inflammatory and fibrotic disorders
Valo Therapeutics Announces Two European Patents Granted for its Lead Asset PeptiCRAd-1 in Immuno-Oncology
SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation
aVaxziPen Announces Positive Data in Multiple Diseases on Novel Needle-Free Vaccine, Thermally Stable Delivery Platform at World Vaccine Congress
Anocca raises SEK 400 million for large-scale development of cancer cell therapies
AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis

Copyright 2020 © Scius Communications | Privacy policy

Website by FisherPaul

  • linkedin
  • X
Link to: Valo Therapeutics selects Exothera to develop large scale oncolytic Adenovirus manufacturing Link to: Valo Therapeutics selects Exothera to develop large scale oncolytic Adenovirus manufacturing Valo Therapeutics selects Exothera to develop large scale oncolytic Adenovirus... Link to: GPCR Therapeutics Announces Launch of US Phase 2 Trial of GPC-100 in Multiple Myeloma Link to: GPCR Therapeutics Announces Launch of US Phase 2 Trial of GPC-100 in Multiple Myeloma GPCR Therapeutics Announces Launch of US Phase 2 Trial of GPC-100 in Multiple...
Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Continue


How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Accept settings